Federal health officials on Thursday backed the public health benefits of nicotine pouches, authorizing Philip Morris International’s Zyn to help adult smokers cut back or quit cigarettes.

Officials proposed limiting the amount of nicotine to make cigarettes less addictive, but it's unclear if the incoming administration will offer support.

FDA authorizes Zyn nicotine pouches, citing public health benefits for adult smokers, despite concerns over flavored products' appeal to teens.

Nicotine pouches are a newer class of smokeless products that don’t contain tobacco. Zyn became the first FDA-authorized brand on Jan. 16.

The FDA authorized the marketing of 20 Zyn products on Thursday, marking the first allowance for the fast-growing nicotine pouches.

The Food and Drug Administration (FDA) announced on Thursday that it authorized the marketing of Zyn nicotine pouches but will be "closely monitoring youth use." Newsweek reached out to Zyn for comment.

The FDA said "an extensive scientific review" found the products were found to pose lower risks of cancer and other serious health conditions compared to cigarettes and smokeless tobacco products.

The FDA announced it has authorized the marketing of 20 Zyn nicotine pouch products, citing their greater health benefits vs. cigarettes and other tobacco products. It is the first time the agency has authorized the sale of nicotine pouches,

Health experts are cheering a move by outgoing President Joe Biden. But, this is terrible news if you're a smoker living in New York.

A new FDA proposal would reduce the amount of feel-good nicotine in cigarettes to near-inconsequential levels.

The Food and Drug Administration (FDA) has announced a groundbreaking proposal to drastically reduce nicotine levels in cigarettes, aiming to curb addiction and encourage smokers to switch to less harmful alternatives or quit altogether.